Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

BACKGROUND: Kidney pain is a common complication in patients with autosomal dominant polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient group. Because pain is d...

Descripción completa

Detalles Bibliográficos
Autores principales: Casteleijn, Niek F., Blais, Jaime D., Chapman, Arlene B., Czerwiec, Frank S., Devuyst, Olivier, Higashihara, Eiji, Leliveld, Anna M., Ouyang, John, Perrone, Ronald D., Torres, Vicente E., Gansevoort, Ron T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497700/
https://www.ncbi.nlm.nih.gov/pubmed/27856088
http://dx.doi.org/10.1053/j.ajkd.2016.08.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497700/
https://www.ncbi.nlm.nih.gov/pubmed/27856088
http://dx.doi.org/10.1053/j.ajkd.2016.08.028

Ejemplares similares